Pharmacology for Nurses · Diabetic Drugs

Insulin and Non-Insulin Injectable Diabetes Drugs

12 min read

On this page 9 sections

In 30 seconds
Why this matters
The college version
Eli explains
Worked example
Key takeaway
Check yourself
Study tools
Sources & references

In 30 seconds

For people whose bodies cannot make enough insulin — everyone with type 1 diabetes and many with type 2 — insulin itself is the treatment. Insulin is a peptide hormone, so it cannot be taken by mouth (the digestive tract would break it down); it must be injected or infused. Modern therapy uses different insulin products to imitate the body's two natural patterns: a steady, low-level basal supply between meals and overnight, and quick bolus bursts after meals. A second group of injectables — the non-insulin injectables, led by the GLP-1 receptor agonists — works with the body's own gut hormones to improve glucose control, often with weight loss as an additional benefit.

This topic covers the insulin classes by their time course, the mechanics and teaching that make insulin therapy safe (injection sites, storage, timing, hypoglycemia preparedness), and the non-insulin injectable classes and their mechanisms. Drug classes and mechanisms are the focus; specific products, onset/peak/duration numbers, doses, and titration schedules vary by manufacturer and guideline and must always be verified against current references and prescriber orders.

Why this matters

Insulin is a : It can save a life or cause life-threatening hypoglycemia within minutes. Safety organizations classify insulin among the medications most likely to cause significant harm when misused — every nursing detail matters.
Insulin therapy is common and growing: With rising rates of type 2 diabetes and the natural progression of the disease, a large share of people with diabetes eventually use insulin. It is also used in hospitals for many people with type 2 during acute illness, surgery, or steroid therapy — not just for people with type 1.
The wrong insulin at the wrong time is a classic error: Insulin products look alike and differ by seconds-to-hours in their time course. Mixing up rapid-acting and long-acting insulin — or giving a mealtime insulin without a meal — is a real, preventable error.
Non-insulin injectables changed the field: GLP-1 receptor agonists improve glucose control, promote weight loss, and are now among the most prescribed diabetes drugs. Nurses administer them, teach people to inject them, and help manage their common GI side effects.
Hypoglycemia teaching is life-saving: Every person on insulin must know the warning signs of low glucose and how to respond. This education is mostly nursing's job.

The college version

Core Concepts

How insulin works

Insulin binds to insulin receptors on cell surfaces, setting off a signaling cascade that moves GLUT4 glucose transporters to the cell membrane. The result: muscle and fat cells take up glucose from the blood, the liver stores glucose as glycogen and stops releasing it, and protein and fat synthesis are promoted. In short, the drug is the hormone — which is why "replacement" is the accurate word.

Insulin classes by time course

Insulin products are classified by how quickly they start working, when they peak, and how long they last. The exact numbers differ by product, concentration, injection site, and individual response — so treat the categories as the concept and verify the details:

Rapid-acting insulins start working quickly, peak early, and are short-lived. They are designed to cover the glucose surge of a meal — taken around the time of eating — and are the usual choice for bolus coverage.
Short-acting (regular) insulins act somewhat more slowly than rapid-acting products but still serve as mealtime (bolus) insulin, with a longer window before onset and a later peak.
Intermediate-acting insulins have a delayed onset and a longer duration, providing a background (basal) supply that covers part of the day or night.
Long-acting insulins release slowly and steadily, providing near-constant basal coverage with a much flatter profile — often given once daily.
Premixed products combine a mealtime insulin with a longer-acting insulin in one vial or pen, trading convenience for less flexibility in adjusting the two components separately.
Concentrated formulations exist (e.g., U-500 and U-300 products) for people needing large doses; these require extra care because the concentration changes the relationship between volume and units — a classic source of dosing error.

The clinical pattern to remember: bolus insulins cover meals, basal insulins cover the background. A typical intensive regimen mimics the healthy pancreas with a long-acting basal product plus rapid-acting boluses at meals. Many people use simpler regimens — premixed products, or basal plus oral drugs — depending on their situation and goals.

Giving insulin safely: the nursing essentials

Units, not volume: insulin is dosed in units, and with concentrated products the volume per unit changes. Always verify the product concentration and the dose in units.
Only insulin syringes or compatible pens/pumps: using the wrong syringe can deliver wildly wrong doses.
Site rotation: injections are typically given into subcutaneous fat (abdomen, thighs, upper arms, buttocks). Rotating sites — and staying within one region for a given injection time — prevents (lumpy fatty tissue that absorbs insulin unpredictably).
Timing relative to meals: rapid-acting insulin is timed to the meal; the exact timing depends on the product and the person's routine — verify the order and teach accordingly.
Storage: unopened insulin is refrigerated; opened products have their own stability windows (often weeks at room temperature, product-specific). Insulin that has been frozen or overheated should not be used.
Never share pens or devices, even between family members — bloodborne pathogen transmission is a documented risk.
Look-alike safety: double-check the product name and concentration, and confirm the right person, dose, route, and time — the classic checks that catch mix-ups between basal and bolus products.
Hypoglycemia preparedness: teach the warning signs (sweating, tremor, palpitations, hunger, confusion), the fast-acting-carbohydrate response for mild lows, and the emergency plan for severe lows when the person cannot swallow safely. The exact treatment steps follow current guidelines and the prescriber's instructions.

Non-insulin injectables: working with the gut hormones

GLP-1 receptor agonists (the class includes exenatide, liraglutide, dulaglutide, and semaglutide) mimic GLP-1, an incretin hormone released from the gut after eating. Their mechanisms are multiple and complementary:

: they boost insulin release from the pancreas — but mainly when glucose is elevated, which lowers the risk of hypoglycemia compared with some other drugs.
Glucagon suppression: they dampen glucagon release, reducing the liver's glucose output.
Slowed gastric emptying: food leaves the stomach more slowly, blunting post-meal glucose spikes and increasing fullness.
Appetite and weight effects: many people lose weight, which is clinically valuable since weight loss improves insulin sensitivity.

Because these effects are glucose-dependent, hypoglycemia is less common when they are used alone; but when combined with insulin or sulfonylureas, the risk rises and the other drug's dose may need adjustment. The most common adverse effects are gastrointestinal — nausea, vomiting, diarrhea — which often improve over time; starting doses are low and titrated slowly for this reason. Class-level warnings include pancreatitis (report severe abdominal pain) and gallbladder events, and these drugs are generally avoided in certain conditions such as medullary thyroid cancer history — the specific contraindications are product-specific and must be verified. They are injected subcutaneously on schedules that range from daily to weekly depending on the product.

Amylin analogs (prototype: pramlintide) mimic amylin, a hormone co-secreted with insulin that slows gastric emptying, suppresses glucagon, and reduces post-meal glucose spikes. Pramlintide is used as an adjunct in people already taking mealtime insulin — it must be given as a separate injection, and the mealtime insulin dose is typically reduced when it is started (under the prescriber's direction) because the combination increases hypoglycemia risk. Nausea is the common dose-limiting adverse effect.

Newer dual and multi-agonist peptides (e.g., agents targeting both GLP-1 and GIP receptors) extend the same incretin logic — check current references for what is available, since this is a fast-moving area of drug development.

Common Confusions

Do not confuse	With	Difference
Rapid-acting insulin	Long-acting insulin	Rapid = fast onset, short duration, mealtime bolus; long-acting = slow, steady, once-daily basal — mixing them up is a classic, dangerous error
Insulin units	Insulin volume (mL)	With concentrated products (e.g., U-500), units and volume diverge — always dose in units and verify concentration
GLP-1 receptor agonists	Insulin	GLP-1 agonists boost the body's own glucose-dependent insulin and suppress glucagon; insulin replaces the hormone outright — GLP-1 agonists alone rarely cause hypoglycemia, insulin can
Basal insulin	Bolus insulin	Background coverage between meals vs. mealtime coverage — different products, different timing
Premixed insulin	A flexible bolus+basal regimen	Premixed is convenient but the two components are locked together, limiting adjustment
Lipohypertrophy	Normal injection-site fat	Lumpy scarred tissue from repeated injections in the same spot; changes absorption and must be avoided by rotation
Injectable diabetes drugs being "the last resort"	Insulin meaning personal failure	Progression to insulin is the natural course of type 2 for many people — framing matters, and person-first language is the standard

Eli explains

The same idea, in plain words

Explain it like I’m 10

Insulin is the key that unlocks cell doors so sugar can get in — and since it's a protein, your stomach would digest it, so it has to be given as a shot or through a pump. There are two kinds of "keys": a slow one that works all day in the background (basal) and a fast one you use at mealtimes (bolus). Some other shots don't give you keys at all — they help your own body make more keys when sugar is high, tell the liver to stop releasing sugar, and slow down how fast food leaves your stomach, so you feel full longer and your sugar doesn't spike.

Worked example

Ms. G., age 60, has had type 2 diabetes for twelve years. Her oral medications no longer keep her glucose in range, and her provider starts a long-acting basal insulin at bedtime, explaining that the pancreas's own insulin output has gradually declined — a natural part of the disease, not a punishment. The nurse's teaching session covers:

The product and the plan: a long-acting insulin taken once daily at the same time, providing background coverage. The nurse shows her the pen, the concentration, and the dose in units, and has her "teach back" how she will select and verify the dose.
Injection technique and rotation: subcutaneous injection into the abdomen or thigh, rotating sites and tracking them so the same spot is not overused; the pen and needle are single-person use only.
Hypoglycemia preparedness: the warning signs (shakiness, sweating, confusion), what to do for a mild low (fast-acting carbohydrate per her plan), and when to seek help; her prescriber has given her a written low-glucose plan to follow.
Storage and travel: where to store the opened pen, what to do if it freezes or overheats, and how to carry supplies when traveling.
What to report: repeated lows, unexplained high glucose, or any confusion about the regimen — no question is too small.

The nurse documents the teaching and the teach-back, and notes that the plan will be adjusted at follow-up based on her glucose records. Later in the chapter's companion topics, oral agents and the GLP-1 injectables complete the picture — but for Ms. G., the immediate lesson is that insulin is safe, predictable, and manageable when the teaching is clear.

Safety note: This scenario illustrates teaching concepts for drug classes only. Specific products, onset/peak/duration profiles, doses, injection timing, storage windows, and hypoglycemia treatment steps vary by manufacturer, guideline, and prescriber order — always verify against current references, the facility formulary, and the prescriber's orders.

Key takeaways

Insulin is a high-alert medication: verify product, concentration, and units; never share pens; watch for look-alike basal/bolus mix-ups.
Basal covers the background; bolus covers meals. Rapid- and short-acting insulins are mealtime bolus products; intermediate- and long-acting insulins provide basal coverage.
Insulin is a peptide and cannot be taken by mouth — injection or infusion only.
Concentrated insulins change the volume-per-unit math and are a known source of dosing errors.
Rotate injection sites to prevent lipohypertrophy; store insulin per product guidance (refrigerated before opening, product-specific rules after).
GLP-1 receptor agonists work through incretin effects: glucose-dependent insulin release, glucagon suppression, slowed gastric emptying, and weight loss; GI upset (nausea) is the common side effect and doses are titrated slowly.
Hypoglycemia risk is additive: combining GLP-1 agonists or amylin analogs with insulin or sulfonylureas raises the risk — doses of the other drugs may need adjustment by the prescriber.
All doses, products, timing, and storage rules must be verified against current references, the facility formulary, and prescriber orders — profiles vary by product and manufacturer.

Check yourself

6 review questions from the chapter. Try each one, then open the answer.

Why can insulin not be taken by mouth, and what does that mean for administration?
Show answer
Insulin is a peptide hormone that the digestive tract would break down, so it cannot be absorbed intact from the gut — it must be injected subcutaneously or infused.
What is the difference between basal and , and which insulin categories serve each role?
Show answer
Basal insulin provides steady background coverage between meals and overnight (intermediate- and long-acting products); bolus insulin covers the glucose rise after meals (rapid- and short-acting products).
Why does site rotation matter for people taking insulin injections?
Show answer
Repeated injection in the same spot causes lipohypertrophy — lumpy tissue that absorbs insulin unpredictably, making glucose control erratic; rotation keeps absorption consistent.
Name three mechanisms by which GLP-1 receptor agonists lower blood glucose, and explain why they carry a lower hypoglycemia risk when used alone.
Show answer
Glucose-dependent insulin secretion (more insulin when glucose is high), suppression of glucagon release, and slowed gastric emptying (plus appetite/weight effects). The glucose-dependence means the drug does little when glucose is normal, so hypoglycemia is uncommon when it is used alone.
Why is insulin classified as a high-alert medication, and what double-checks follow from that?
Show answer
Because misuse — wrong product, wrong concentration, wrong timing, wrong dose — can cause severe harm within minutes, including life-threatening hypoglycemia. The double-checks: verify product, concentration, units, person, route, and time; never share pens; treat concentrated products with extra care.
When an is added to mealtime insulin, why might the prescriber adjust the insulin dose?
Show answer
Because both drugs affect post-meal glucose handling and the combination increases hypoglycemia risk — the mealtime insulin dose is typically reduced when the amylin analog is started, under the prescriber's direction.

Keep learning

Ready to build on this? Continue to the next lesson.

Study toolsKey vocabulary

Key vocabulary

Basal insulin: Long-acting background insulin covering between-meal and overnight needs
Bolus insulin: Mealtime insulin that covers the glucose surge after eating
GLUT4 transporter: The glucose "door" that insulin moves to the cell surface
Incretin hormones: Gut hormones (e.g., GLP-1) released after eating that help control glucose
GLP-1 receptor agonist: Injectable drug class that mimics GLP-1's glucose-lowering and appetite effects
Glucose-dependent insulin secretion: Insulin release that increases mainly when glucose is high
Lipohypertrophy: Lumpy fatty tissue at overused injection sites that absorbs insulin unpredictably
Amylin analog: Injectable drug mimicking amylin to slow gastric emptying and blunt post-meal spikes
High-alert medication: A drug with heightened risk of significant harm when misused
Premixed insulin: A fixed combination of bolus and basal insulin in one product

Sources & references

openstax.org — Pharmacology

This lesson was adapted from the open educational references above; their licenses and attributions are preserved. See Copyright & Licensing.

Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.